New hope for Drug-Resistant lung cancer: triple therapy shows promise in early trial
NCT ID NCT04285671
First seen Mar 10, 2026 · Last updated Apr 29, 2026 · Updated 8 times
Summary
This study is for people with advanced EGFR-mutated lung cancer that no longer responds to the drug osimertinib. Researchers are adding two other targeted antibodies, trastuzumab and necitumumab, to osimertinib to see if the combination can shrink tumors and control the disease. About 30 participants will receive the treatment to find the safest dose and measure how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.